Harrow Beats on EPS and Revenue, Yet Analysts Split Sharply on the Stock

Harrow (NASDAQ:HROW) posted quarterly earnings of $0.25 per share on Monday, beating analysts' consensus of $0.19 by $0.06. Revenue came in at $99.30 million against estimates of $98.59 million — a modest top-line beat of roughly 0.7%.

The beat is real, but the profitability picture underneath it is rougher. The ophthalmic pharmaceutical company (a maker of prescription eye-care therapies) reported a negative net margin of 13.51% and a negative return on equity of 38.00%. In plain words: Harrow sold more than Wall Street expected and still lost money doing it.

How did the market react?

Shares rose 2.2% on Monday, adding $0.58 to close at $27.47. Trading volume hit 1,162,138 shares — nearly double the stock's average of 691,479 — suggesting the earnings news pulled in fresh attention.

The valuation and balance-sheet backdrop:

• Market capitalization: $1.03 billion
• Price-to-earnings ratio: -27.47 (negative because the company is unprofitable)
• Beta: 0.18, meaning the stock moves far less than the overall market
• Debt-to-equity ratio: 19.70
• Quick ratio: 2.08; current ratio: 2.24 (both measure short-term liquidity; above 1 signals comfortable coverage of near-term obligations)

Technicals tell a harder story. The stock trades at $27.47 against a 50-day simple moving average of $31.43 and a 200-day average of $37.82. Its 12-month range spans $25.76 to $54.85 — the shares currently sit just above the floor.

What are insiders doing?

Insider Amir Shojaei sold 11,250 shares on Friday, August 14th, at an average price of $40.00, for a total of $450,000.00. After the sale, Shojaei directly owned 11,250 shares valued at $450,000 — a 50.00% cut in their position. The transaction was disclosed in a Securities and Exchange Commission filing. Corporate insiders still own 12.80% of the stock.

An insider halving their stake at $40.00, well above the current $27.47 price, is the kind of signal desk analysts flag. In short: someone with inside visibility sold high.

Where do Wall Street analysts stand?

The sell side is split, and the tone has cooled in recent months:

• BTIG Research restated a "buy" rating and a $63.00 price target on Wednesday, October 7th
• Leerink Partners initiated coverage on Wednesday, September 9th with an "outperform" rating and a $45.00 price objective
• Wall Street Zen upgraded the stock from "sell" to "hold" on Saturday, August 15th
• Weiss Ratings reaffirmed a "sell (e+)" rating on Friday, October 16th
• Zacks Research downgraded Harrow from "hold" to "strong sell" on Tuesday, November 3rd

The tally across ten firms: seven Buy ratings, one Hold, two Sell. Per MarketBeat.com data, that works out to a consensus rating of "Moderate Buy" with a consensus price target of $66.17 — more than double Monday's close.

That gap between the $66.17 target and the $27.47 price is the tension in this story. Bulls see a beaten-down growth name with momentum on revenue; bears, including Zacks as recently as November 3rd, see persistent losses and a leveraged balance sheet.

What does Harrow actually sell?

Harrow develops, acquires and commercializes prescription therapies for eye care, targeting the ocular surface, anterior segment and retina. Its commercial products include VEVYE, a cyclosporine ophthalmic solution for dry eye disease, and IHEEZO, a chloroprocaine hydrochloride ophthalmic gel used for ocular surface anesthesia during procedures.

A revenue beat, a widening analyst divide, and a stock still 50% below its 12-month high.